Articles
May 20, 2025
Alnylam Publishes 2024 Corporate Responsibility Report
We've published our 2024 Corporate Responsibility Report detailing our efforts in our pillars: Patients, Science, Employees, Communities, Planet, and Governance
Read More ›
May 1, 2025
Challenge Accepted: How Culture Powers Innovation at Alnylam
Alnylam's Chief Human Resources Officer discusses how the company's culture powers innovation and our mission to transform lives through RNAi therapeutics.
Read More ›
March 25, 2025
2024 Year in Review & Look Ahead: CEO Yvonne Greenstreet Highlights a Pivotal Year for Aln ...
Alnylam CEO Yvonne Greenstreet reflects on the company's accomplishments in 2024 and highlights of the 2024 annual report.
Read More ›
February 21, 2025
A New Therapeutic Approach Seeks to Silence Devastating Neurological Diseases
Exploring the potential of RNAi therapeutics to tackle brain diseases with few or no treatments
Read More ›
February 3, 2025
Alnylam Named a Newsweek Most Responsible Company for 2025
Alnylam has been named one of Newsweek's America's Most Responsible Companies for 2025, our third year in a row.
Read More ›
January 9, 2025
Supporting Refugees in Europe: Alnylam Challengers and the Path to Empowerment
Arun Skaria, Alnylam's Head of DEI and Corporate Responsibility provides an update on Alnylam's efforts to support refugees in Europe
Read More ›
December 5, 2024
Celebrating a Decade on The Boston Globe’s Top Place to Work List
Alnylam Named a Best Place to Work for the 10th Year in a Row by The Boston Globe
Read More ›
October 22, 2024
Driven by Science: Alnylam Named a Science Magazine Top Employer 6 Years in a Row
Alnylam has been named a top science employer by Science magazine for the 6th year in a row.
Read More ›
October 3, 2024
Better Together: Collaborating for Rare Disease Care, Pharmacy Innovation Network
One critical way to address this goal is through strategic collaborations such as the Pharmacy Innovation Network (PIN),
Read More ›
September 26, 2024
Confronting the World’s Leading Killer with a New Therapeutic Approach
For Xicang Guo and Jiaming Zhang, one particular condition remains stubbornly beyond their control – hypertension, also known as high blood pressure.
Read More ›
